Surgically Resected Esophageal Squamous Cell Carcinoma: Patient Survival and Clinicopathological Prognostic Factors.
Dong Young JeongKyung Soo LeeJoon Young ChoiMyung Jin ChungYang Won MinHong Kwan KimJae Ill ZoYoung Mog ShimJong-Mu SunPublished in: Scientific reports (2020)
We aimed to report patients' survival after surgical resection of eSCC and to ascertain the clinical, imaging, and pathological factors related to patient prognosis. This retrospective study included 435 patients with eSCC of <stage T2 (median follow-up period, 49.3 months). A total of 103 (23.7%) patients died, and 89 (20.5%) experienced recurrence during follow-up. The maximum standardized uptake value (SUVmax) on positron emission tomography (PET)/computed tomography (CT) of the primary tumor was significantly correlated with tumor length, nodal metastasis, and pathologic T stage in a positive linear fashion. In the multivariate analysis, higher SUVmax on PET/CT was a negative prognostic factor for both disease-free survival (DFS) and overall survival (OS). Contrarily, the presence of nodal metastasis was a prognostic factor only for DFS, and pathologic T stage only for OS. By applying SUVmax cut-off, both DFS and OS were significantly different among three groups when divided by cut-off values (A: SUVmax ≤ 3.05, B: SUVmax 3.06 - 5.64, C: SUVmax ≥ 5.65). In patients with a surgically resectable eSCC, measuring the SUVmax of the primary tumor during PET/CT can help predict patient survival. Additionally, PET/CT renders triage criterion for endoscopic submucosal dissection (ESD; T1a cancer and SUVmax, ≤3.05).
Keyphrases
- prognostic factors
- pet ct
- positron emission tomography
- computed tomography
- free survival
- neoadjuvant chemotherapy
- case report
- magnetic resonance imaging
- lymph node
- pet imaging
- squamous cell carcinoma
- end stage renal disease
- chronic kidney disease
- endoscopic submucosal dissection
- locally advanced
- high resolution
- image quality
- dual energy
- ejection fraction
- radiation therapy
- photodynamic therapy
- lymph node metastasis